Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351275 | 0.90 | KDM4E (0.62) | HTTKDM4EPKMSMN1; SMN2NPC1 | |
| SCHEMBL31333958 | 0.88 | DRD2 (0.59) | HTTKDM4EPKMSMN1; SMN2NPC1 | |
| SCHEMBL25232232 | 0.86 | KDM4E (0.58) | HTTKDM4EPKMSMN1; SMN2NPC1 | |
| SCHEMBL31334376 | 0.84 | SMN1; SMN2 (0.57) | ALDH1A1HTTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL31333438 | 0.84 | KDM4E (0.56) | HTTKDM4EPKMSMN1; SMN2NPC1 | |
| SCHEMBL31617924 | 0.83 | NAMPT (0.56) | HTTKDM4EPKMSMN1; SMN2NPC1 | |
| SCHEMBL6981012 | 0.83 | SMN1; SMN2 (0.65) | ALDH1A1HTTKDM4EPKMSMN1; SMN2 | |
| SCHEMBL1939593 | 0.83 | SMN1; SMN2 (0.65) | ALDH1A1HTTKDM4EPKMSMN1; SMN2 | |
| SCHEMBL13668666 | 0.83 | SYK (0.57) | DRD2CYP2C9CYP3A4CKS1BSKP1 | |
| SCHEMBL13666981 | 0.83 | SYK (0.57) | DRD2CYP2C9CYP3A4CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015325-B2 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2006-03-21 | — | — | US | disclosed |
| US-6960588-B1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2005-11-01 | — | — | US | disclosed |
| EP-1244643-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030083344-A1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-1244643-A1 | TRYPTASE INHIBITORS | ALTANA Pharma AG (DE) | 2002-10-02 | — | — | EP | disclosed |
| EP-1216236-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001046168-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001019809-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083344-A1 | Tryptase inhibitors | TPSAB1, TPSB2, TPSG1 | ALDH1A1 779/4885HTT 2669/4885KDM4E 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.